(Q36200409)

12 August 2017

1 reference

title

Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation (English)

1 reference

12 August 2017

1 reference

1 reference

Gellrich S

1

1 reference

12 August 2017

Muche JM

2

1 reference

12 August 2017

Wilks A

3

1 reference

12 August 2017

Jasch KC

4

1 reference

12 August 2017

Voit C

5

1 reference

12 August 2017

Fischer T

6

1 reference

12 August 2017

Audring H

7

1 reference

12 August 2017

Sterry W

8

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

British Journal of Dermatology

12 August 2017

published in

1 reference

12 August 2017

volume

153

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

167-173

1 reference

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06659.X

10.1111/J.1365-2133.2005.06659.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference